Compare Bristol-Myers Squibb Co (BMY) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.45 (market cap $116.30B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.79. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| BMY | HYG | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Fixed Income |
52-Week High | $62.37 | $81.32 |
52-Week Low | $42.60 | $78.72 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
HYG trades at $79.52, down 0.24% with a bearish technical outlook indicated by 17 sell signals against 2 buy signals. The ETF maintains dividend distributions, with recent payouts of $0.42 in May 2026 and $0.41 in June 2026. Market sentiment is cautious amid Federal Reserve uncertainty and elevated put volume in high-yield bonds, reflecting investor concerns about interest rate hikes and inflation pressures.
Outlook remains challenged by macroeconomic headwinds and potential Fed tightening, though dividend yield provides income support. Key risks include interest rate volatility and narrowing market breadth. Investors should weigh yield attractiveness against duration risk in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
